Skip to content

Ketamine for addiction: all studies

Page 11 of 15: studies 101 to 110 of 144, newest first. Back to the ketamine for addiction overview

Research

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

American Journal of Psychiatry January 11, 2022 Meryem Grabski, Amy Mcandrew, Will Lawn et al. 169 citations

OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol...

Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.

Frontiers in Psychiatry 2022 Udo Bonnet, Michael Specka, Ann-Kristin Kanti et al. 4 citations

There is a lack of benefit/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts. We extended the analyses of substance harm/benefit assessments of German addiction medicine experts (N = 101), in parts reported recently in this journal [doi.org/10.3389/fpsyt.2020.59219], by the perspectives of...

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review

BJPsych Open December 23, 2021 Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al. 180 citations

Background In the past two decades, subanaesthetic doses of ketamine have been demonstrated to have rapid and sustained antidepressant effects, and accumulating research has demonstrated ketamine's therapeutic effects for a range of psychiatric conditions. Aims In light of these findings surrounding ketamine's psychotherapeutic potential, we systematically review the extant evidence on...

Therapeutic potential of ketamine for alcohol use disorder.

Neuroscience & Biobehavioral Reviews July 1, 2021 Stephen D Worrell, Thomas J Gould 47 citations

Excessive alcohol consumption is involved in 1/10 of deaths of U.S. working-age adults and costs the country around $250,000,000 yearly. While Alcohol Use Disorder (AUD) pathology is complex and involves multiple neurotransmitter systems, changes in synaptic plasticity, hippocampal neurogenesis, and neural connectivity have been implicated in the behavioral characteristics of AUD. Depressed...

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Brain Sciences June 27, 2021 Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso et al. 114 citations

The obsessive-compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive-compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control...

DOI: 10.3390/brainsci11070856 (opens in new tab) Ketamine Eating disorders Obsessive compulsive Substance use +2

Widespread Cortical Thickness Reductions Following Non-medical Use of Ketamine: a Structural MRI Study of Individuals with Ketamine Dependence

medRxiv Preprint Server February 21, 2021 Jinsong Tang, Qiuxia Wu, Chang Qi et al. preprint

Background A version of ketamine, called Esketamine has been approved for treatment-resistant depression (TRD). Ketamine (“K powder”), a “dissociative” anesthetic agent, however, has been used non-medically alone or with other illicit substances. Our previous studies showed a link between non-medical ketamine use and brain structural and functional alterations. We found dorsal prefrontal gray...

DOI: 10.1101/2021.02.21.21252178 (opens in new tab) Full text (opens in new tab) Ketamine abuse Recreational ketamine use Illicit ketamine Ketamine dependence +11

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial.

Journal of Psychopharmacology February 1, 2021 Rebecca L Rothberg, Nour Azhari, Nancy A Haug et al. 95 citations

Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects. The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary...

"This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.

Frontiers in Psychiatry 2021 Özden Merve Mollaahmetoğlu, Johanna Keeler, Katherine J Ashbullby et al. 62 citations

Background: The therapeutic benefits of ketamine have been demonstrated for a variety of psychiatric disorders. However, the role of ketamine induced psychoactive experiences in mediating the therapeutic effects is unclear. Despite the growing quantitative research on the efficacy of ketamine treatment, very few studies examined participant experiences of ketamine infusions in a treatment...

Combining Ketamine, Brain Stimulation (rTMS) and Mindfulness Therapy (TIMBER) for Opioid Addiction

Cureus November 1, 2020 B. Pradhan, Garrett Rossi

Opioid addiction in the United States currently presents a national crisis despite availability of different treatments. Prior findings suggest that both repetitive transcranial magnetic stimulation (rTMS) and subanesthetic dose of ketamine are efficacious in patients with opioid use disorders (OUD) when administered in isolation. However, their therapeutic value may be undermined by varying...

R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder.

Pharmacology, Biochemistry, and Behavior April 22, 2020 Jeffrey M. Witkin, J. Kranzler, K. Kaniecki et al. 33 citations

Substance abuse disorder continues to have devastating consequences for individuals and society and current therapies are not sufficient to provide the magnitude of medical impact required. Although some evidence suggests the use of ketamine in treating various substance use related- symptoms, its adverse event profile including dissociation, dysphoria, and abuse liability limit its potential...